Business Context and Reporting Period
This Form 8-K Current Report was filed by Compass Therapeutics, Inc. on February 10, 2023, covering events occurring on February 8, 2023. The Company is a Delaware corporation with its principal executive offices in Boston, Massachusetts, and its common stock trades on the NASDAQ Capital Market under the symbol CMPX. The filing reports the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and director compensation arrangements rather than financial performance.
Material Changes
The primary material change reported is the appointment of David Wurzer, CPA, as a new Class III director, effective immediately. Mr. Wurzer was also appointed as a member and chairman of the Audit Committee. The Board determined that Mr. Wurzer is an independent director and qualifies as an "audit committee financial expert."
Guidance, Outlook, and Management Commentary
The filing contains no guidance, outlook, or management commentary regarding the Company's business strategy or future financial performance. Regarding the new director's compensation, Mr. Wurzer will receive:
- A cash retainer of $45,000 for general Board availability and participation.
- An additional $10,000 cash retainer for his service as chairman of the Audit Committee.
- An initial option award to purchase 50,000 shares of common stock at the closing price on the grant date, vesting monthly over four years.
No unusual items, risks, or contingencies were disclosed in this specific filing.
Key Facts for Investor Verification
- David Wurzer has been appointed as an independent director and Audit Committee Chairman.
- Mr. Wurzer's total annual cash compensation for Board service is $55,000.
- Mr. Wurzer received an option grant for 50,000 shares with a four-year vesting schedule.
- The appointment fills a vacant Class III Board seat with a term expiring at the 2023 annual meeting.
- No financial performance data is included in this report.